The U.S. Department of Homeland Security (DHS) Science and Technology Directorate (S&T) has announced intentions to issue a new sole source contract to Omni Array Biotechnology for the continued development of its laboratory-based B. anthracis detection and diagnostic assays.
In the existing contract, Omni Array was selected to develop a rapid Anthrax diagnostics test and also a multiplex (Luminex-based) rapid Abrin detection test.
Omni Array is developing the novel multiplex Anthrax biomarker assay for clinical diagnostics testing and is at the completion stages of the rapid multiplex Abrin detection test. In addition to these efforts, Omni Array was also contracted to support DHS efforts in the validation of immunoassays to biothreat agents as a third party evaluation site.
The overall objective of the contracts is to develop and deploy novel and innovative rapid first responder, clinical diagnostic, and biothreat agent detection assays capable of fulfilling the needs of multiple agencies and departments by multiplexing assays to detect simultaneously select biothreat agents.